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Gene expression signatures in motor neurone disease fibroblasts reveal dysregulation of
metabolism, hypoxia-response and RNA processing functions
Aims: Amyotrophic lateral sclerosis (ALS) and primary
lateral sclerosis (PLS) are two syndromic variants within
the motor neurone disease spectrum. As PLS and most
ALS cases are sporadic (SALS), this limits the availability
of cellular models for investigating pathogenic mecha-
nisms and therapeutic targets. The aim of this study was
to use gene expression profiling to evaluate fibroblasts as
cellular models for SALS and PLS, to establish whether
dysregulated biological processes recapitulate those seen
in the central nervous system and to elucidate pathways
that distinguish the clinically defined variants of SALS
and PLS. Methods: Microarray analysis was performed on
fibroblast RNA and differentially expressed genes identi-
fied. Genes in enriched biological pathways were validated
by quantitative PCR and functional assays performed to
establish the effect of altered RNA levels on the cellular
processes. Results: Gene expression profiling demon-
strated that whilst there were many differentially
expressed genes in common between SALS and PLS fibro-
blasts, there were many more expressed specifically in the
SALS fibroblasts, including those involved in RNA process-
ing and the stress response. Functional analysis of the
fibroblasts confirmed a significant decrease in miRNA pro-
duction and a reduced response to hypoxia in SALS fibro-
blasts. Furthermore, metabolic gene changes seen in
SALS, many of which were also evident in PLS fibroblasts,
resulted in dysfunctional cellular respiration. Conclu-
sions: The data demonstrate that fibroblasts can act as
cellular models for ALS and PLS, by establishing the tran-
scriptional changes in known pathogenic pathways that
confer subsequent functional effects and potentially high-
light targets for therapeutic intervention.
Keywords: amyotrophic lateral sclerosis, cell models, fibroblasts, hypoxia response, microarray, microRNA, primary
lateral sclerosis
Introduction
Amyotrophic lateral sclerosis (ALS) is a fatal adult onset
neurodegenerative disease characterized by the relent-
lessly progressing degeneration of both upper and lower
motor neurones (UMN and LMN) of the motor cortex,
brainstem and spinal cord. Symptom onset is predomi-
nantly in the upper or lower limbs, or in the bulbar mus-
culature; in rare instances, it presents in the respiratory
muscles [1]. The disease survival is usually 2–3 years from
symptom onset, though 5% of cases may survive over
10 years [2]. ALS is the most common variant of a spec-
trum of motor neurone diseases (MND), encompassing
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syndromic variants including primary lateral sclerosis
(PLS), progressive muscular atrophy (PMA) and progres-
sive bulbar palsy (PBP). The variants differ primarily in
which type of motor neurone degenerates and the rate of
disease progression.
PLS, which accounts for 2.9–3.7% of MND, is clini-
cally defined following 4 years of exclusive UMN involve-
ment [3]. In contrast to ALS, PLS is associated with a
more benign disease course of up to 17 years [4].
Although pathological hallmarks of ALS such as TDP-43
immunoreactive ubiquitinated inclusions have been
observed in PLS [5], due to the rarity of the cases and
less aggressive disease progression, there has been a
paucity of studies investigating aetiological mechanisms
in PLS specifically. There is, however, substantial overlap
in the clinical presentation between MND variants, as
cases presenting with PLS can go on to develop LMN
degeneration accompanied by a rapidly progressing phe-
notype, with time to LMN involvement indicative of
disease duration [4,6].
In familial ALS (FALS), which accounts for 5% of all
ALS cases, mutations in genes such as SOD1, TARDBP,
FUS, VAPB, VCP and ALS2, have provided invaluable
insights into pathogenic mechanisms of disease. Whilst
the function of the recently identified C9ORF72 protein
and the effect of the expanded G4C2 repeat in intron 1 have
yet to be established [7,8], the repeat in C9ORF72 has
recently been estimated to account for 39% of FALS and
4–8% of SALS cases [9]. The clinical and genetic hetero-
geneity of ALS, presents a significant hurdle in modelling
the sporadic disease, and despite having an estimated her-
itability of 0.61 [10], a robust marker for SALS has not yet
been identified. In contrast to ALS, PLS is generally
sporadic.
The clinical and pathological picture of FALS and SALS
are largely similar with motor neurone death occurring as
a culmination of complex gene-environment interactions
and the activation of multiple pathophysiological mecha-
nisms including oxidative stress, dysregulation of RNA
processing, mitochondrial dysfunction, protein aggrega-
tion, excitotoxicity, disordered axonal transport and
inflammation [11]. However, preclinical in vitro and in vivo
trials focusing on FALS models of the disease, which may
not adequately model sporadic disease, have led to a
failure in translation of therapies into clinical benefits in
ALS [12]. Thus, there is a need for surrogate models of
disease that are representative of the genetic and environ-
mental background of individual patients. The aim of this
study was to determine the expression profiles of a surro-
gate tissue from SALS and PLS patients and to establish if
these fibroblasts can act as a cellular model for these
disease states. The use of fibroblasts from non-genetic
variants allows us to explore the transcriptional changes
underlying dysregulated processes that recapitulate
central nervous system (CNS) pathogenic mechanisms
and additionally identify biological processes that underlie
the pathological distinction between clinically defined
variants of ALS and PLS.
Gene expression profiling in cell culture models and
post-mortem tissue of transgenic animals and ALS
patients has provided valuable insights into ALS patho-
genesis [13]. The ease of obtaining and cell culturing skin
fibroblasts make them a valuable model system to study
neurodegenerative mechanisms. Previous reports have
demonstrated abnormalities in mechanisms relevant to
neurodegeneration such as response to oxidative stress,
alterations in energy metabolism and calcium handling in
fibroblasts cultured from Alzheimer’s disease, Parkinson’s
disease and ALS patients [14–17]. By using gene expres-
sion profiling in fibroblasts, we have identified many tran-
scriptional alterations in common between SALS and PLS
fibroblasts, whilst also determining that SALS fibroblasts
showed significantly more changes in genes involved in
RNA processing and the response to stress. These data
demonstrate a proof-of-principle for the usefulness of
fibroblasts as a disease model to study pathophysiological
mechanisms, to identify targets amenable to therapeutic
intervention and to screen potential disease modifying
drugs in SALS and PLS.
Materials and methods
Patient details
Experiments were carried out using fibroblasts obtained
from SALS patients, PLS patients and healthy, neurologi-
cally normal controls (Table S1). Patients with SALS met
the El Escorial criteria for definite or probable ALS.
Patients were classified as PLS following 4 years of exclu-
sive UMN involvement. None of the patients included in
this study carried mutations in the most common ALS
genes, SOD1, TARDBP, FUS and C9ORF72. The average
age at disease onset in the ALS cohort was 57 years (range
38–74 years) with average disease duration of 3 years
(range 1–6 years) at the time of sampling. In the PLS
cohort, the average age at disease onset was 55 years
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(range 45–70 years), with an average disease duration of
13 (range 9–20 years) at the time of sampling.The average
age of controls was 53 years (range 37–76 years).
Fibroblast cultures
Skin biopsies were obtained from the forearm of subjects
under sterile conditions after informed consent in accord-
ance with guidelines set by the local ethics committee.
Fibroblast cell cultures were established at the Metabolic
Biochemistry Unit, Sheffield Children’s Hospital NHS
Foundation Trust. Monolayers of primary fibroblast cell
cultures were routinely maintained in T75 flasks with
fibroblast cell culture medium Ham’s F-10 Media (Gibco,
Life Technologies, Paisley, UK) containing 10% foetal calf
serum (Biosera, Labtech International, Uckfield, UK), 1%
penicillin-streptomycin antibiotic solution, 0.25% holo-
transferrin and 2.5 ng epidermal growth factor (all from
Sigma, Gillingham, UK), in incubators at 37°C supple-
mented with 20% O2 and 5% CO2 unless stated other-
wise. Cultures at 70–80% confluency were serially
passaged by washing with PBS and treatment with
trypsin (0.5 μg/l)-EDTA (0.2 μg/l). Fibroblast cell lines
were maintained and used up to passage 11. For the
hypoxia experiments, fibroblasts from control and
patients were cultured for an additional 18 h simultane-
ously in normoxia conditions (20% O2) as well in a 1% O2
hypoxic chamber.
RNA extraction, amplification, fragmentation
and labelling
RNA was isolated from 6 SALS, 6 PLS and 6 control fibro-
blast cultures using the RNeasy Mini Kit (Qiagen, Man-
chester, UK) as per the manufacturer’s protocol. RNA was
linearly amplified and biotin labelled using the One-Cycle
Affymetrix Labelling Kit (Affymetrix, High Wycombe, UK)
as per the manufacturer’s protocol. Biotin-labelled cRNA
was fragmented to 35–200 bp fragments by heating to
95°C for 35 min with a fragmentation buffer (Affymetrix)
and subsequently hybridized overnight at 42°C to Human
U133 Plus 2.0 GeneChips as per the Eukaryotic Target
Hybridisation protocol (Affymetrix). GeneChips were
stained and washed in a GeneChip Fluidics Station 400
(Affymetrix). The fluorescence intensity of hybridized
transcripts was determined with the high-resolution laser
of the GeneChip 3000 Scanner (MegAllele system,
Affymetrix).
Microarray analysis
Background correction, normalization and summariza-
tion of GeneChip fluorescence intensities to derive signal
intensities by incorporating a scaling and weighting of
experimentally observed inherent thermodynamic proper-
ties of every contributing PM/MM probe pair was carried
out using PLIER (Probe Logarithmic Intensity Error) algo-
rithm in GeneSpring GX 11 (Agilent Technologies,
Wokingham, UK). One-wayanova and Tukey post hoc test
was applied to detect differential expression across the
SALS, PLS and healthy control groups. Transcripts were
defined as differentially expressed if they differed between
groups with a fold change of >1.5 fold and a P-value of
<0.05. Where a gene was represented by more than one
transcript, the most significant transcript was retained for
further analysis. Differentially expressed transcripts were
classified according to their biological function based on
GO terms identified by NetAffx™ (Affymetrix) and DAVID
(Database for Annotation, Visualisation and Integrated
Discovery) [18]; DAVID was then used to identify Gene
Ontology (GO) biological processes and molecular
functions enriched in the list of differentially expressed
transcripts.
Q-PCR validation
12.5 ng of total RNA from 11 ALS cases, 6 PLS cases and
10 controls (Table S1) was reverse transcribed using
Superscript III and oligo-dT primers as per the manufac-
turers protocol (Invitrogen, Life Technologies, Paisley, UK)
and used along with 1× Brilliant II SYBR Green PCR
Master Mix (Stratagene, Agilent Technologies, Cheadle,
UK) and optimized concentrations of forward and reverse
primers in each assay (Table S2). The assays were run on
an MX3000P Real-Time PCR system (Stratagene) with
appropriate RT negative reactions without Superscript III.
For each gene of interest, the fluorescent signal intensity
was analysed using the MxPro software (Stratagene) and
its gene expression value normalized to housekeeping
gene beta-actin (ACTB) using the 2ΔΔCt method (ABI
PRISM 7700 Sequence Detection System protocol,
Applied Biosystems, Warrington, UK). The ACTB gene was
chosen as a suitable housekeeping gene due to its stable
expression across all patient and control fibroblasts on the
microarray chips. Expression levels for each gene are
expressed relative to their expression levels in control
fibroblasts. Statistical significance of expression levels
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between disease and controls was assessed on applying an
unpaired Student’s t-test using GraphPad Prism 6
(GraphPad Software Inc., California, USA).
Metabolic measurements using Seahorse assays
Fibroblasts from 6 SALS patients and 9 controls
(Table S1) were plated at 50 000 cells/well in a 24 well
Seahorse cell culture plate (Seahorse Bioscience, Copen-
hagen, Denmark) in 250 μl minimal media (PAA) supple-
mented with 10% FCS gold (PAA), 2 mM glutamine
(Lonza, Basel, Switzerland), 50 μg/ml uridine (Sigma),
100× vitamins (Lonza 5 ml in 500 ml), 100× amino
acids (Lonza 5 ml in 500 ml), sodium pyruvate (Lonza
5 ml in 500 ml) and penicillin/streptomycin (Lonza 5 ml
in 500 ml 5000 U/ml). The cells were incubated at
37°C/5% CO2 overnight. The following day the media was
removed and the cells were washed with 1000 μl XF
Assay Media pH 7.4 (Seahorse Bioscience) supplemented
with 1 mM sodium pyruvate, 2 mM glutamine and
1mg/ml D-glucose (Sigma). Cells were incubated at 37°C
in a non CO2 incubator for 1 h in a total volume of 675 μl
of XF Assay media. Meanwhile, a 24 well microplate was
loaded with 2.5 mg/ml oligomycin (Sigma), final concen-
tration 0.25 mg/ml. 5.0 μM FCCP (Sigma), 0.5 μM final
concentration and 5.0 μM rotenone (Sigma), final con-
centration 0.5 μM. All were made up in assay media as
described above. The microplate was calibrated in a
Seahorse XF24 analyser prior to addition of the cell
culture plate. Three basal oxygen consumption rate
(OCR) and extracellular acidification rate (ECAR) meas-
urements were recorded prior to addition of the
mitochondrial inhibitors. The cells were measured three
times for 3 min each. Cell number was normalized by
addition of 2.5 μM calcein (Invitrogen) incubated with
the cells for 60 min and fluorescence measured on a
Fluorostar Omega plate reader (BMG Labtech, Ortenberg,
Germany) at Ex485nm/Em520nm.
MicroRNA profiling of fibroblasts
Total RNA was extracted from 6 SALS and 6 control T75
fibroblast culture flasks using the mirVana isolation kit
(Applied Biosystems) according to the manufacture’s pro-
tocol. TaqMan® Low Density Arrays (TLDAs) were used to
measure the expression level of 377 microRNAs (miRNAs)
(Applied Biosystems). Briefly, extracted RNA was used in
megaplex reverse transcription reactions containing
miRNA specific stem loop primers (Applied Biosystems).
Following subsequent pre-amplification, the expression of
miRNA was measured using Q-PCR with TLDA cards
(Human A v3.0). The card data were analysed on an ABI
7900HT Q-PCR system using Sequence Detection System
(SDS) software v2.3 according to the manufacturer’s rec-
ommended conditions. Manual inspection of amplification
plots and preliminary data analysis were performed using
SDS RQ manager v1.2 and Data Assist software v2.0
respectively (Applied Biosystems). Relative expression of
mature miRNAs was calculated using the competitive CT
2ΔΔCt method, with stably expressed miRNAs across all
samples, (as identified using NormFinder algorithm [19],
acting as controls to normalize the data.
Immunoblotting for hypoxic response
in fibroblasts
Total protein was extracted by washing cells twice in PBS
and scraping into 100 μl cell lysis RIPA buffer (150 mM
NaCl, 1% IGEPAL® CA-630, 0.5% sodium deoxycholate,
0.1% SDS, 50 mM Tris pH 8.0, plus protease inhibitor
cocktail) (Sigma) at 4°C. Protein concentration was deter-
mined by the colorimetric Bradford assay using Coomassie
Brilliant Blue dye (Bio-Rad, Hemel Hempstead, UK). 80 μg
of total protein along with pre-stained protein ladder
(Bioline, London, UK) was separated on 10% sodium
dodecyl sulphate polyacrylamide gel (SDS-PAGE). Protein
samples were transferred overnight onto polyvinylidene
difluoride (PVDF) membrane (Millipore, Watford, UK) and
blocked in PBS-T and 5% (w/v) dried skimmed milk. The
blots were then probed in PBST plus milk with mouse
polyclonal anti HIF-1α (R&D Biosciences, Abingdon, UK)
diluted 1:500, rabbit polyclonal anti-PHD2 (Abcam, Cam-
bridge, UK) diluted 1:1000 and rabbit polyclonal anti-
tubulin (Abcam) diluted 1:5000. To detect HIF-1α, the
blot was incubated for 4 h at room temperature; to detect
PHD-2 and tubulin incubation was for 1 h at room tem-
perature. Subsequently, each blot was probed for 1 h at
room temperature with peroxidase conjugated goat anti-
mouse secondary antibody diluted 1:6000 (for HIF-1α) or
goat anti-rabbit secondary antibody diluted 1:4000 (for
PHD-2 and tubulin). Antibody bound to protein was
detected by enhanced chemiluminescence (ECL) kit
(Amersham, GE Healthcare Life Sciences, Little Chalfont,
UK) as per the manufacturer’s protocol. Protein quantifi-
cation was carried out using GBox-HR Gel Doc system
(Syngene, Cambridge, UK).
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VEGF ELISA
To quantify VEGF protein levels, supernatants were col-
lected, spun down to remove cellular debris and tested for
VEGF protein using Quantikine VEGF ELISA kit (R&D
Biosciences) as per the manufacturer’s protocol.
Results
Microarray analysis
The transcriptional profiles generated from all fibroblasts
showed comparable quality control parameters with an
average of 42.3% of transcripts called as present in SALS
fibroblasts, 42.4% in PLS fibroblasts and 42.3% in control
fibroblasts (CEL files have been submitted to the Gene
Expression Omnibus Repository, Accession GSE56808).
Comparative analysis using GeneSpring identified 416 sig-
nificantly differentially expressed transcripts in SALS
(Table S3). A more subtle 209 transcripts in PLS fibro-
blasts were differentially expressed compared to controls
(Table S4). The majority of transcripts in the SALS and
PLS fibroblasts showed a decrease in expression, compared
to controls and of those genes differentially expressed in
PLS, 118 transcripts (56%) were in common and were
regulated in the same direction in SALS fibroblasts
(Figure 1).
Differentially expressed transcripts were functionally
categorized using GO terms identified by NetAffx™ and
DAVID. Of those transcripts differentially expressed in
SALS fibroblasts, there were a large number of genes
involved in transcription, signalling, metabolism and RNA
processing (Table 1) and this was supported by analysis in
DAVID, which demonstrated a highly significant enrich-
ment of biological processes involving ‘transcription’,
several ‘regulation of transcription’ related GO terms
including ‘regulation of gene expression, epigenetic’ and
‘glucose homeostasis’ (Table 2). In PLS fibroblasts, tran-
scription, signalling and metabolism again showed the
largest number of genes differentially expressed, similar to
the SALS fibroblasts (Table 1). However, there was a strik-
ing decrease in the number of genes involved in RNA pro-
cessing and response to stress compared to SALS, whilst
more cell adhesion genes were differentially expressed in
the PLS fibroblasts. DAVID analysis identified the ‘response
to estrogen stimulus’, as the most significantly enriched in
Figure 1. Gene expression analysis showing the number of differentially expressed genes pairwise comparisons between the SALS vs.
control fibroblasts and PLS vs. controls fibroblasts. The number of genes that are differentially expressed in common between ALS and PLS
vs. controls are also shown. (Differentially expressed genes are defined as those showing an FC of ≥1.5 and a P-value of ≤0.05 between the
disease group and control fibroblasts.)
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Table 1. Biological functions altered in SALS and PLS fibroblasts and number of genes annotated for each process following categorization
based on terms identified by NetAffx™ and DAVID
SALS fibroblasts PLS fibroblasts SALS vs. PLS
Biological function
No. of
genes Biological function
No. of
genes
Ratio of genes
differentially expressed
Transcription 63 Transcription 25 2.52
Signalling 41 Signalling 26 1.58
Metabolism 30 Metabolism 25 1.20
RNA processing 28 RNA processing 8 3.50*
Protein catabolism 15 Protein catabolism 6 2.50
Cytoskeleton 14 Cytoskeleton 6 2.33
Response to stress 14 Response to stress 2 7.00*
Cell cycle 12 Cell cycle 6 2.00
Cell adhesion 10 Cell Adhesion 17 0.59
Immune response 7 Immune response 7 1.00
Protein transport 7
Apoptosis 5 Apoptosis 3 1.67
Ion transport 5 Ion transport 4 1.25
Protein translation 3 Protein transport 4 0.75
Protein processing 2
Miscellaneous 35 Miscellaneous 14 2.50
Unknown 125 Unknown 56 2.23
The relative number of genes differentially expressed in SALS compared with PLS fibroblasts is also provided. *Response to stress and RNA
processing are the categories which are altered most in SALS, compared with the PLS fibroblasts.
Table 2. Top 20 gene ontology biological processes altered in SALS fibroblasts as determined by the functional annotation chart using the
DAVID analysis software
Gene ontology biological process
No. of
genes
% differentially
expressed genes P-value
GO:0006350∼transcription 84 22.05 7.13E-10
GO:0045449∼regulation of transcription 96 25.20 1.65E-09
GO:0051252∼regulation of RNA metabolic process 73 19.16 1.21E-08
GO:0006355∼regulation of transcription, DNA-dependent 69 18.11 1.39E-07
GO:0006357∼regulation of transcription from RNA polymerase II promoter 34 8.92 1.45E-05
GO:0010608∼posttranscriptional regulation of gene expression 15 3.94 1.15E-04
GO:0040029∼regulation of gene expression, epigenetic 9 2.36 1.73E-04
GO:0042593∼glucose homeostasis 7 1.84 4.66E-04
GO:0033500∼carbohydrate homeostasis 7 1.84 4.66E-04
GO:0010605∼negative regulation of macromolecule metabolic process 30 7.87 5.21E-04
GO:0016071∼mRNA metabolic process 19 4.99 6.26E-04
GO:0010629∼negative regulation of gene expression 23 6.04 7.01E-04
GO:0010558∼negative regulation of macromolecule biosynthetic process 24 6.30 8.74E-04
GO:0043009∼chordate embryonic development 17 4.46 0.0013
GO:0009792∼embryonic development ending in birth or egg hatching 17 4.46 0.0014
GO:0042127∼regulation of cell proliferation 30 7.87 0.0015
GO:0032350∼regulation of hormone metabolic process 4 1.05 0.0016
GO:0009890∼negative regulation of biosynthetic process 24 6.30 0.0016
GO:0008380∼RNA splicing 15 3.94 0.0022
GO:0006397∼mRNA processing 16 4.20 0.0026
For each process, the number and percentage of differentially expressed genes and the statistical significance has been shown.
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the PLS fibroblasts (Table 3), though 5 of the 9 genes in
this category were also altered in SALS fibroblasts and of
the 20 genes in the wider GO term ‘response to organic
substance’ only 7 were specific for PLS. Thus, as demon-
strated from the initial categorization, SALS fibroblast
gene profiles show more significant and specific gene
expression changes compared to PLS fibroblasts.
RNA processing and the stress response have been iden-
tified previously to play a role in ALS pathogenesis. We
therefore hypothesized that the significantly and highly
enriched differential expression of these processes in SALS
fibroblasts are mimicking CNS neurodegenerative mecha-
nisms, and involve genes that underlie the pathological
distinction between SALS and PLS. In contrast, the
common biological pathways of metabolism, signalling
and transcription may provide a therapeutic target for
both disease variants, and the greatest degree of correla-
tion between PLS and SALS was in the metabolic genes
(with 11 in common). For the purpose of this manuscript,
downstream analysis of the data has focused on these
three biological categories: (i) metabolism, (ii) RNA pro-
cessing and (iii) response to stress, using Q-PCR validation
and functional assays in SALS and control fibroblasts to
evaluate the validity of fibroblasts as a cell model for SALS.
Metabolism and energy production
Fibroblasts mainly rely on ATP generated via glycolysis to
meet their energy requirements [14]. SALS fibroblasts
exhibit significant transcriptional changes in energy
metabolism genes, including those in the insulin-mediated
signalling cascade, glycolytic and lipid homeostatic path-
ways. The expression profiling data suggest that the
dysregulation of insulin signalling and glycolysis results
in a compensatory increase in fatty acid oxidation to gen-
erate ATP via β-oxidation (Figure 2 and Table 4).
Insulin signalling Binding of insulin or insulin-like
growth factor to the insulin receptor (IR) and insulin-like
growth factor receptor (IGF1R) activates a signalling
pathway which leads to localization of the glucose trans-
porters at the plasma membrane ready for glucose uptake,
and increased transcription of glucose and lipid metabo-
lism genes in the nucleus. In the fibroblasts of SALS
patients the expression of IR and IGF1R were both
decreased (IR −3.08; IGF1R −2.56) and the decrease in
IGF1R was consequently confirmed by Q-PCR (P = 0.03)
(Figure 3). In addition, there was differential expression of
two proteins which bind to the insulin-like growth factor 2
Table 3. Top 20 gene ontology biological processes altered in PLS fibroblasts as determined by the functional annotation chart using the
DAVID analysis software
Gene ontology biological process
No. of
genes
% differentially
expressed genes P-value
GO:0043627∼response to estrogen stimulus 9 4.64 2.46E-05
GO:0009719∼response to endogenous stimulus 16 8.25 5.51E-05
GO:0010559∼regulation of glycoprotein biosynthetic process 4 2.06 2.19E-04
GO:0009725∼response to hormone stimulus 14 7.22 2.72E-04
GO:0032355∼response to estradiol stimulus 6 3.09 3.51E-04
GO:0010033∼response to organic substance 20 10.31 5.01E-04
GO:0042493∼response to drug 10 5.15 7.82E-04
GO:0030217∼T cell differentiation 6 3.09 8.29E-04
GO:0033273∼response to vitamin 6 3.09 8.89E-04
GO:0051252∼regulation of RNA metabolic process 36 18.56 9.09E-04
GO:0030098∼lymphocyte differentiation 7 3.61 0.001101
GO:0006355∼regulation of transcription, DNA-dependent 35 18.04 0.0012
GO:0010560∼positive regulation of glycoprotein biosynthetic process 3 1.55 0.0012
GO:0006357∼regulation of transcription from RNA polymerase II promoter 19 9.79 0.0014
GO:0045449∼regulation of transcription 46 23.71 0.0015
GO:0048545∼response to steroid hormone stimulus 9 4.64 0.0015
GO:0042113∼B cell activation 6 3.09 0.0017
GO:0030183∼B cell differentiation 5 2.58 0.0021
GO:0014070∼response to organic cyclic substance 7 3.61 0.0025
GO:0035137∼hindlimb morphogenesis 4 2.06 0.0030
For each process, the number and percentage of differentially expressed genes and the statistical significance has been shown.
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(IGF2) mRNA, IGF2 mRNA binding proteins 1 and 2
(IGF2BP1 +3.8 and IGF2BP2 −1.6). These were originally
identified to regulate IGF2 translation, with IGF2BP1
inhibiting translation, whilst IGF2BP2 enhanced transla-
tion. However, subsequent work has shown that IGF2BPs
have many mRNA targets, resulting in either inhibition
or enhancement of translation or inhibition of mRNA
decay [20].
Glycolysis In SALS fibroblasts, there was a decrease in
glucose transporter 3 (SLC2A3/GLUT3 −1.63), the
glucose transporter which is highly expressed in neurones
and which has the highest glucose affinity of the four
transporters [21]. The differential expression of SLC2A3/
GLUT3 was confirmed by Q-PCR (P = 0.01) (Figure 3).
There was decreased expression of glucose metabolism
genes including phosphoglucomutase-2 like 1 (PGM2L1
−1.62), which controls the rate of glycolytic flux, and
phosphoglycerate kinase (PGK1 −1.74), which catalyses
the first ATP producing step of glycolysis, although Q-PCR
validation of PGK1 did not reach statistical significance
(P = 0.12) (Figure 3). Transcriptional changes were also
seen in cytosolic adenylate kinase 1 (AK1 +1.64) and
nucleoside disphosphate kinase A (NDPKA/NME1
+1.61), which along with PGK1 are involved in a tightly
regulated enzymatic network that permits the transfer of
high-energy phosphoryl groups (in the form of ATP)
between energy producing and energy consuming sites
within the cell [22]. The increased expression of AK1 and
NDPKA may be an attempt to compensate for the reduc-
tion in ATP caused by reduced PGK1 expression. In con-
trast, the processed pseudogene AK4 (also known as
AK3L1) was decreased (AK4 −1.53).
The tricarboxylic acid (TCA) cycle is predicted to be dis-
rupted by a decrease in dihydrolipoamide s-succinyl
transferase (DLST −1.5), which encodes the E2 component
of the α-ketoglutarate enzyme of the TCA cycle. In addi-
tion, the PRKAA2 subunit of AMP activated protein
kinase (PRKAA2 −1.55), which acts as a central check-
point monitoring systemic and cellular energy status and
its downstream target forkhead box O3 (FOXO3 −1.68)
were both decreased. PRKAA2 was subsequently validated
by Q-PCR (P = 0.01) (Figure 3). Thus the collective down-
regulation of insulin signalling along with key glycolytic
enzymes, indicates a dysfunction in glycolysis driven
energy generation in SALS fibroblasts.
Fatty acid oxidation SALS fibroblasts showed an
increased expression of solute carrier 27 family A member
4 (SLC27A4/FATP4 +1.57), the principal fatty acyl-CoA
synthetase in skin fibroblasts for the activation of
very long chain fatty acids and their entry into the
Figure 2. Schematic representation of the differentially expressed genes in the SALS fibroblasts compared to controls which are involved in
metabolic pathways and their corresponding protein localizations within the cell. Red arrows indicate there is an increase in the expression
of the gene; blue arrows indicate a decrease in gene expression.
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Table 4. Genes involved in metabolism, RNA processing, response to stress and cell survival which are differentially expressed in SALS
fibroblasts compared to controls
Gene symbol Gene name Fold change P-value
Metabolism
AGXT2L2 Alanine-glyoxylate aminotransferase 2-like 2 −1.51 0.027
AK1 Adenylate kinase 1 +1.64 0.0001
AK4/AK3L1 Adenylate kinase 4/ adenylate kinase 3 like 1 −1.58 0.015
B4GALT1 UDP-Gal:beta-GlcNAc beta-1,4-galactosyltransferase 1 −2.41 0.001
DLST E2 componenet of oxo-glutarate complex −1.51 0.004
EBP Emopamil binding protein (sterol isomerase) +1.74 0.005
FADS2 Fatty acid desaturase 2 −3.23 0.0002
FOXO3 Forkhead box 3 −1.68 0.001
IGF1R Insulin like growth factor-1 receptor −2.56 0.040
IGF2BP1 Insulin-like growth factor 2 mRNA binding protein 1 +3.83 0.003
IGF2BP2 Insulin-like growth factor 2 mRNA-binding protein 2 −1.63 0.031
IR Insulin receptor −3.08 0.011
NDUFS7 NADH-coenzyme Q reductase +1.54 0.008
NDUFS8 NADH dehydrogenase ubiquinone Fe-S 8 +1.69 0.002
NME1/NDPKA Non-metastatic cells 1/ nucleoside disphosphate kinase A +1.61 0.002
NP Purine nucleoside phosphorylase +1.56 0.042
PDE7B Phosphodiesterase 7B −1.60 0.028
PGK1 Phosphoglycerate kinase 1 −1.74 0.034
PGM2L1 Phosphoglucomutase 2-like 1 −1.62 0.010
PPA2 Pyrophosphatase (inorganic) 2 −1.52 0.037
PRKAA2 AMP-activated protein kinase alpha 2 catalytic subunit −1.55 0.013
PRPS2 Phosphoribosyl pyrophosphate synthetase 2 −3.10 0.046
SC4MOL Sterol-C4-methyl-oxidase like −1.56 0.040
SCD Stearoyl-CoA desaturase (delta-9-desaturase) −1.78 0.026
SCD5 Stearoyl-CoA 9-desaturase −1.97 0.007
SLC25A36 Solute carrier family 25, member 36 −1.72 0.003
SLC25A37 Solute carrier family 25, member 37 −2.49 0.026
SLC27A4/FATP4 TP4FATP4/FATP4/ Solute carrier family 27 (fatty acid transporter) member 4 +1.57 0.006
SLC2A3/GLUT3 Solute carrier family 2 (facilitated glucose transporter) member 3 −1.63 0.002
RNA processing
AGO1/EIF2C1 Argonaute 1/Eukaryotic translation initiation factor 2C 1 −1.54 0.040
AGO2/EIF2C2 Argonaute 2/Eukaryotic translation initiation factor 2C 2 −2.22 0.011
DGCR8 DiGeorge syndrome critical region 8 −1.52 0.021
DICER1 Dicer1, Dcr-1 homolog −2.03 0.047
EXOSC4 Exosome component 4 +1.53 0.004
FUS Fused in sarcoma −1.79 0.018
G3BP1 GTPase activating protein (SH3 domain) binding protein 1 +1.53 0.024
HNRNPD Heterogenous nuclear ribonucleoprotein D −1.64 0.006
HNRNPM Heterogenous nuclear ribonucleoprotein M −1.65 0.024
HNRNPU Heterogenous nuclear ribonucleoprotein U −1.85 0.031
KHSRP FUSE-binding protein 2 −1.94 0.019
LSM4 U6 snRNP-associated Sm-like protein 4 +1.52 0.032
MBNL1 Muscleblind-like 1 −1.97 0.012
NXF3 Nuclear RNA export factor 3 −1.58 0.021
PCBP2/HNRNPE2 Poly(rC) binding protein 2/ heterogeneous nuclear ribonucleoprotein E2 −2.14 0.039
PRMT7 Protein arginine methyltransferase 7 +1.54 0.011
QK1 Quaking, mouse homolog of −1.53 0.011
RBMS3 RNA binding motif protein, single strand-interacting 3 −2.03 0.019
RBPMS RNA binding protein gene with multiple splicing −1.57 0.004
SFRS18 Splicing factor, arginine/serine-rich 18 −1.62 0.006
SNRPA1 Small nuclear ribonucleoprotein polypeptide A’ −1.72 0.020
TAF15 TAF15 RNA polymerase II, TAT box binding protein −1.65 0.034
TAF9B TAF9B RNA polymerase II, TATA box binding protein (TBP)-associated factor −2.33 0.006
TRA2A Transformer 2 alpha homolog (Drosophila) −2.57 0.017
WHSC2 Wolf-Hirschhorn syndrome candidate 2 −1.54 0.013
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mitochondrial β-oxidation pathway [23]. This was con-
firmed by Q-PCR (P = 0.02) (Figure 3). Translocase of
outer mitochondrial membrane 22 (TOMM22 +1.69
fold), which is a part of the protein transport machinery
needed for the mitochondrial import of nuclear proteins
involved in oxidative phosphorylation and lipid metabo-
lism, was also increased in SALS fibroblasts. In contrast,
fatty acid desaturases, which are responsible for the con-
version of saturated fatty acids to mono and polyunsatu-
rated fatty acids (MUFA and PUFA), were decreased in
SALS fibroblasts (FADS2 −3.23, SCD −1.78 and SCD5
−1.78). The MUFA and PUFA are constituents of phospho-
lipids, triglycerides and cholesterol esters that are essential
constituents of cell membranes, vital stores of energy and
regulators of signalling mechanisms [24]. Differential
expression of FADS2 was confirmed by Q-PCR (P = 0.03)
(Figure 3). These transcriptional changes suggest that
SALS fibroblasts may be correcting for the energy deficit
in carbohydrate metabolism by shutting down fatty acid
synthesis and driving ATP production through fatty
acid oxidation.
RNA processing
RNA processing is an important level of post-
transcriptional regulation of gene expression and it
encompasses a wide range of spatiotemporally linked
functions including RNA splicing, nucleo-cytoplasmic
transport, translational silencing and RNA degradation,
Table 4. (Continued)
Gene symbol Gene name Fold change P-value
WTAP Wilms tumour 1 associated protein −2.19 0.048
ZFP36L2 Zinc finger protein 36, C3H type-like 2 −1.65 0.049
Response to stress (and cell survival)
AKR1C4 Aldo-keto reductase family 1, member C4 +1.76 0.024
ARNT/HIF1B Aryl hydrocarbon receptor nuclear translocator −2.4 0.017
ARNT2 Aryl hydrocarbon receptor nuclear translocator 2 −1.74 0.008
BIRC5 Baculoviral IAP repeat-containing protein 5 +1.65 0.020
DDAH1 Dimethylarginine dimethylaminohydrolase 1 −3.21 0.020
DUSP1 Dual specificity phosphatase 1 +1.82 0.028
EP300 Histone acetyltransferase p300 −1.87 0.026
FAC1 Foetal Alzheimer antigen −2.05 0.009
FOS v-fos FBJ murine osteosarcoma viral oncogene homolog +2.43 0.004
GPX1 Glutathione peroxidase 1 +1.57 0.039
HIF1A Hypoxia inducible factor 1A −1.65 0.032
MCL1 Myeloid cell leukemia sequence 1 (BCL2-related) −1.64 0.020
MINK1 Misshapen-like kinase 1 −1.58 0.003
PDCD6 Programmed cell death 6 −1.67 0.043
PENK Enkephalin A +4.24 0.012
PHLDA1 Pleckstrin homology-like domain, family A, member 1 +1.60 0.014
RBBP6 Retinoblastoma-binding protein 6 −1.60 0.0002
STEAP3 STEAP family member 3 +1.52 0.001
ZAK Leucine zipper and sterile alpha motif-containing kinase −2.02 0.038
The full list of genes differentially expressed in SALS fibroblasts is provided in Table S3.
Figure 3. Q-PCR validation of genes involved in glucose and fatty
acid metabolism in SALS fibroblasts (n = 11) compared to control
fibroblasts (n = 11): IGF1R, SLC2A3/GLUT3, PGK1, PRKAA2,
SLC27A4/FATP4 and FADS2. Error bars indicate SEM. *P ≤ 0.05;
**P < 0.01.
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as well as non-coding RNA production. SALS fibroblasts
exhibit a specific and marked down-regulation of multiple
transcripts involved in different RNA metabolic processes
(Table 4).
RNA binding and RNA splicing proteins Of particular inter-
est in this category was the decreased expression of
the FALS-associated nucleo-cytoplasmic shuttling RNA
binding protein fused in sarcoma (FUS −1.79), which is
involved in RNA splicing and regulation of transcription.
This differential expression was subsequently validated by
Q-PCR (P = 0.003) (Figure 4). Decreased expression of
other transcripts involved in splicing included the small
nuclear ribonucleoprotein polypeptide A1 (SNRPA1
−1.72), a component of the U2 snRNP particle, splicing
factor arginine/serine-rich 18 (SFRS18 −1.62) and
the large heterogeneous nuclear ribonucleoproteins
HNRNPD, HNRNPM and HNRNPU (HNRNPD −1.64;
HNRNPM −1.65; HNRNPU −1.85). Other RNA binding
proteins that showed decreased expression were RNA
binding protein with multiple splicing (RBPMS −1.57),
RNA binding motif, single stranded interacting protein 3
(RBMS3 −1.65) and Wilms tumour associated protein 1
(WTAP1 −2.19), which is known to associate with splicing
factors in nuclear speckles [25]. Interestingly, RBPMS
interacts with QK1, encoded by the human homolog of the
mouse quaking gene, which is also decreased (QK1 −1.53)
and involved in RNA splicing, export and mRNA stability.
In contrast to the extensive decreased expression of other
RNA metabolism genes, expression of the ribosomal RNA
processing protein 41/exosome component 4, which is
involved in degradation of mRNA containing AU-rich ele-
ments in the 3′UTR, was increased (EXOSC4 +1.53).
miRNA processing An important aspect of post-
transcriptional regulation is controlled by microRNAs
(miRNAs) that bind target mRNAs, thereby either tagging
them for degradation or for translation inhibition [26,27].
During miRNA synthesis, the pri-miRNA is transcribed by
RNA polymerase II/III and then undergoes sequential pro-
cessing; firstly by the microprocessor complex comprising
of nuclear ribonuclease III (RNASEN/DROSHA) and
DiGeorge syndrome critical region 8 (DGCR8), resulting in
the formation of a pre-miRNA, which is then exported out
of the nucleus to the cytoplasm by exportin 5, where it is
then processed by the endoribonuclease DICER complex to
produce a double stranded miRNA. Whilst the comple-
mentary strand is degraded, the mature miRNA is loaded
onto the RNA-induced silencing complex (RISC) alongside
argonaute proteins (AGO/EIF2C), in order to bind to target
mRNA molecules and inhibit translation [28].
SALS fibroblasts demonstrated decreased expression of
key transcripts involved in miRNA processing, including
the RNA polymerase II enzyme TAF15 (−1.65), the micro-
processor complex gene DGCR8 (−1.52), the gene encod-
ing DICER1 (−1.62) and the RISC proteins AGO1/EIF2C1
(−1.54) and AGO2/EIF2C2 (−2.22). The differential
expression of DICER (P = 0.001) and AGO1 (P = 0.0004)
were confirmed by Q-PCR (Figure 4). Additionally, the
KH-type splicing regulatory protein (KHSRP/Fuse binding
protein 2), which is a component of both DICER and
DROSHA complex that optimizes the positioning and/or
recruitment of both complexes during miRNA biogenesis
showed decreased expression (KHSRP −1.94 fold) [29]
and as did the poly(Rc) binding protein 2, which interacts
with DICER to promote miRNA processing [30] (PCBP2/
HNRNPE2 −2.14). This protein, which localizes to
P-bodies and stress granules [31] was validated by Q-PCR
(P = 0.007) (Figure 4).
SALS fibroblasts also exhibited alterations of other RNA
binding proteins, which in contrast to the other genes in
this functional category, were increased. These included
GTPase activating protein (SH3 domain) binding protein 1
(G3BP1 +1.53), which is involved in stress granule assem-
bly, and U6 snRNA-associated Sm-like protein 4 (LSM4
+1.52), which is associated with snRNP complexes that
include the U6 snRNA.
Figure 4. Q-PCR validation of genes involved in miRNA processing
and oxidative stress in SALS fibroblasts (n = 11) compared to
control fibroblasts (n = 11): FUS, DICER, AGO1, PCBP2 and FAC1.
Error bars indicate SEM. **P ≤ 0.01, ***P ≤ 0.001.
ALS & PLS fibroblasts as cell models for sporadic disease 211
NAN 2015; 41: 201–226© 2014 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
Response to cellular stress
SALS fibroblasts exhibit alteration of transcripts linked to
several different cellular adaptive responses to physiologi-
cal stresses including hypoxia and oxidative stress
(Table 4). These dysregulated responses appear to be com-
pensated by other cellular pathways which are differen-
tially expressed in favour of a pro-survival transcriptional
programme.
Hypoxic stress The brain is the main consumer of
energy and is therefore particularly susceptible to
neuronal damage and cell death arising from oxygen dep-
rivation [32]. The adaptive response to hypoxia, which is
propagated by hypoxia-inducible transcription factors
(HIF), has been linked to neuroprotection and decreased
cell death of neurones. Fibroblasts from SALS fibroblasts
have down-regulation of both subunits encoding the
heterodimeric HIF-1 protein, HIF1A (HIF1A −1.65) and
HIF1B (HIF1B/ARNT −2.40 and ARNT2 −1.74). There is
also a decrease in histone acetyltransferase p300 (EP300
−1.87), a chromatin modifier that acts as a co-activator
of HIF1A mediated transcriptional changes. The hypoth-
esized impairment in the response to hypoxia may also be
associated with the observed down-regulation of GLUT3
and glycolytic enzymes (as described above), which are
downstream targets of HIF-1 [33].
Oxidative stress SALS fibroblasts exhibit alterations in
genes involved in the NRF2 mediated anti-oxidant
response to oxidative stress. NRF2 is a transcription factor
which, under basal conditions is confined to the cytoplasm
bound to KEAP1. Upon oxidative stress, NRF2 is
translocated to the nucleus where it binds anti-oxidant
response elements in ‘programmed cell life‘ gene promoters
and initiates expression. Foetal Alzheimer antigen, a zinc
finger DNA binding partner of KEAP1 which competes
with NRF2 for KEAP1 binding showed decreased expres-
sion (FAC1 −2.03), whilst v-FOS FBJ osteosarcoma onco-
gene homolog (FOS +2.43), which forms the AP-1
transcription factor with C-JUN to inhibit NRF2 responses
[34] was increased. Overall, this predicts a reduced anti-
oxidant response in a disease known to exhibit increased
oxidative stress. FAC1 differential expression was con-
firmed by Q-PCR (P < 0.01) (Figure 4). In fact, the only
evidence of a positive response to increased oxidative stress
was an increase of glutathione peroxidase 1 (GPX1+1.57),
which is an anti-oxidant enzyme that catalyses the degra-
dation of hydrogen peroxide.
Cell survival To counteract the increased hypoxic and
oxidative stress, several compensatory responses are
evident. The transcriptional increase of dual specificity
phosphatase 1 (DUSP1 +1.82), an inhibitor of the p38
pathway which is activated in primary embryonic fibro-
blasts following oxidative stress is increased, whilst there
is a concomitant decrease of p38 activators leucine
zipper and sterile alpha motif containing kinase (ZAK
−2.02) and misshapen-like kinase 1 (MINK1 −1.58),
thereby potentially limiting p38 propagation of inflam-
mation and apoptosis. Nitric oxide is an activator of the
p38 pathway, and there is evidence to suggest NO
production is reduced, with decreased expression of
dimethylarginine dimethylaminohydrolase 1 (DDAH1
−3.21), an enzyme responsible for activating neuronal
nitric oxide synthase (NOS) via the degradation of asym-
metric dimethylarginine (ADMA).
In addition, there were several apoptotic genes differen-
tially expressed. The pro-apoptotic gene programmed cell
death 6 (PDCD6 −1.67) was decreased, whilst there were
increases in the pro-survival genes baculoviral IAP repeat
containing 5 (BIRC5 +1.72) and pleckstrin homology-like
domain family A member 1 (PHLDA1 +1.60), mounting a
survival response. In contrast, the anti-apoptotic myeloid
leukaemia sequence 1 (MCL1), which binds to BAK to
inhibit its interaction with p53 and subsequent
cytochrome C release, is decreased (−1.64), whilst STEAP
family member 3 (STEAP3), a pro-apoptotic protein down-
stream of p53 was increased (+1.52).
Functional validation
Metabolic assessment of SALS fibroblasts The differential
expression of metabolic genes suggests a decrease in
glycolysis in SALS fibroblasts, which is compensated by an
increase in fatty acid oxidation. To determine whether
these gene changes had an effect on the metabolism of live
cells, the metabolic profile of SALS fibroblasts was meas-
ured under basal conditions using Seahorse XF-24
bioanalyser. This showed that SALS fibroblasts had a sig-
nificantly reduced basal cellular oxygen consumption rate
(COCR) compared to age matched controls (Figure 5a). To
determine whether this drop in COCR was mitochondrial
specific, the complex I inhibitor rotenone was added to the
cells and the remaining OCR (which is non-mitochondrial
respiration) was subtracted from total COCR. The data
indicate that mitochondrial OCR (MOCR) was signifi-
cantly reduced in the SALS patients (Figure 5b). When
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oligomycin was added to the cells to determine the level of
mitochondrial oxygen consumption linked to ATP synthe-
sis, the SALS patients showed a significant reduction in
coupled respiration compared to controls (Figure 5c)
though no difference was observed between controls and
SALS patients in terms of uncoupled MOCR (data not
shown). Basal extracellular acidification rate (ECAR) is a
measure of glycolytic flux via lactate production. No sig-
nificant differences were observed between controls and
SALS cases (Figure 5d), although there was evidence of
age dependent effects (data not shown). When the ATP
synthase inhibitor oligomycin is added to the cells, the
cells normally respond by up-regulating glycolysis to cope
with the ATP energy deficit. This increase in glycolysis
above basal levels gives an indication of the glycolytic
capacity of the cells, a measure of glycolytic function. In
Figure 5. Oxygen consumption defects in SALS fibroblasts. (a) Basal Cellular Oxygen Consumption analysed in assay media supplemented
with 1 mg/ml glucose, 1 mM sodium pyruvate and 2 mM glutamine. (b) Basal Mitochondrial Oxygen Consumption calculated by
subtracting OCR in the presence of rotenone from total cellular OCR. **P ≤ 0.01 Mann–Whitney unpaired t-test. (c) Coupled respiration in
SALS patients. Oxygen consumption linked to ATP synthesis was determined by injection of 0.25 μg/ml oligomycin and measuring
respiration three times over a 25 min period in XF assay media. *P < 0.05 (d) Basal ECAR. (e) Glycolytic capacity, calculated by analysing the
increase in ECAR in the presence of oligomycin and normalizing the increase to basal ECAR as a percentage. **P ≤ 0.01 logit transformation
followed by Mann–Whitney unpaired t-test. n = 3 per patient, Error bars indicate SEM.
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the fibroblasts, when normalizing to basal levels (in order
to overcome age dependent effects), the control cases were
able to up-regulate glycolysis by 148%, in the presence of
oligomycin, whereas the SALS cases showed significantly
reduced glycolytic capacity (128%) (Figure 5e).
miRNA dysregulation in SALS fibroblasts There were sig-
nificant decreases in the expression of multiple RNA pro-
cessing genes, including those involved in miRNA
biogenesis. To determine the effect of these changes on
miRNA levels in the fibroblasts, miRNA analysis was per-
formed on 6 SALS and 6 control fibroblast samples. Of the
227 miRNAs detected in all of the samples, 19 were sig-
nificantly differentially expressed over 1.5 fold (P < 0.05).
All of these were decreased in SALS compared to control
fibroblasts (Table S5). Visualization of the miRNA expres-
sion data on a volcano plot showed there was a marked
decrease in the levels of miRNAs in SALS compared to
controls (Figure 6), further demonstrating an overall
dysregulation of miRNA biogenesis in the SALS samples.
Of the 19 miRNAs differentially expressed, 5 have been
previously described as being involved in hypoxia, through
regulating or being regulated by the HIF proteins. In addi-
tion, 10 have also been found to be differentially expressed
following knockdown of FUS in the SK-N-BE neuroblas-
toma cell line [35], whilst in contrast, miR-142-5p and
miR-155 have previously been shown to be increased in
ALS rodent models and human spinal cord [36,37].
Effect of hypoxia on SALS fibroblasts To determine the
functional significance of the transcriptional changes in
hypoxia response genes that were identified by microarray
analysis, transcript levels of HIF1A, HIF1B/ARNT and
ARNT2, as well as the hypoxia induced gene VEGF were
measured by Q-PCR following an 18 h incubation in 1%
O2. The SALS fibroblasts failed to exhibit a significant
increase in the intrinsic ability to up-regulate HIF1B/
ARNT, ARNT2 and VEGF, whereas control fibroblasts
showed significant increases in HIF1B/ARNT and VEGF
following hypoxia (Figure 7a–c). ARNT2, although
increased in control fibroblasts, did not reach significance.
Unexpectedly, however, HIF1A showed a significant
decrease in gene expression in control fibroblasts, as well
as decreased expression in SALS, following hypoxia
(Figure 7d).
HIF1A and HIF1B are both usually constitutively
expressed with the HIF-1 protein transcriptional activity
usually regulated through post-translational modifica-
tions (PTMs) to amino acid residues on HIF1A [38].
However, we have demonstrated in SALS fibroblasts a sig-
Figure 6. Volcano plot to display fold change vs. P-value from T-test comparison of SALS and control fibroblast miRNA expression profiles.
Green dots and red dots represent miRNAs down or up regulated >1.5 fold respectively in SALS samples. The purple line represents the
P = 0.05 level of significance.
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nificant decrease in gene expression of HIF1A and HIF1B,
as well as the HIF-1 co-activator, p300. Therefore, assays
were developed to measure the protein levels of HIF1A in
hypoxic control and SALS fibroblasts. Under normal con-
ditions, the HIF1A protein is tagged for degradation,
thereby limiting accumulation in the cell. However,
during hypoxia, the HIF1A protein is stabilized by PTMs,
translocated into the nucleus where it dimerises with the
HIF1B/ARNT transcription factor. Protein levels of HIF1A
were compared between control and SALS fibroblasts by
western blotting following 18 h in 1% O2. As expected,
hypoxic control fibroblasts showed a significant increase of
HIF1A protein in comparison with control fibroblasts cul-
tured in normal conditions (FC = 6.9, P = 0.02), whilst
hypoxic SALS fibroblasts displayed a minimal increase in
HIF1A compared to SALS fibroblasts cultured in normal
conditions (FC = 1.74, P = 0.45) (Figure 8a,b). The sig-
nificant difference in HIF1A protein levels following
hypoxia between controls and SALS fibroblasts (FC =
4.71, P = 0.04) supports the QPCR data that there is an
impaired response to hypoxia in SALS fibroblasts.
To investigate this impairment further, VEGF protein
levels were measured by ELISA in cell supernatants of 6
control and 6 SALS fibroblasts following 18 h under
normal conditions and under hypoxia (1% O2.) After nor-
malizing to cell number, secretion of VEGF protein was
determined as significantly increased in hypoxic control
fibroblasts compared to controls cultured under normal
conditions (FC = 2.9, P = 0.002) (Figure 8c). In contrast,
whilst SALS fibroblasts had a marginally higher level of
VEGF at baseline compared to controls (P = 0.3), they
failed to show a statistically significant increase following
hypoxia (FC = 1.6, P = 0.2). Thus, the evidence indicates
that the hypoxic response in SALS fibroblasts is impaired.
Discussion
Transcriptome analysis of SALS and PLS fibroblasts was
performed to establish whether dysregulated processes in
the CNS are recapitulated in cells derived from peripheral
tissues, such that these cells may be used as a cellular
model to investigate disease pathophysiology where the
Figure 7. Response of fibroblasts to hypoxia. Intrinsic ability of SALS (n = 6) and control fibroblasts (n = 6) to up-regulate transcript levels
of HIF1B/ARNT, ARNT2, VEGF and HIF1A following hypoxia. Error bars indicate SEM. *P ≤ 0.05, **P ≤ 0.01.
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Figure 8. Western blotting of HIF1A protein levels and ELISA quantification of VEGF protein. (a) Representative western blot of HIF1A
protein (120Kda) in control and SALS fibroblast under normal and hypoxic (1% O2) conditions, using beta-tubulin (50Kda) as a loading
control. SALS fibroblast (lane 4) shows decreased HIF1A protein levels on comparison with control (lane 2) following hypoxia.
(b) Quantification of HIF1A protein in SALS fibroblasts (n = 6) compared to controls (n = 6) under normal and hypoxic (1% O2) conditions.
HIF1A protein levels relative to beta-tubulin were measured by densitometry and this showed significantly decreased levels of HIF1A in
SALS compared to control fibroblasts following hypoxia. (c) Quantification of VEGF protein in SALS fibroblasts (n = 6) and controls (n = 6) in
response to hypoxia. After hypoxia, VEGF levels were significantly higher in control (P = 0.02) but not patient (P = 0.2) fibroblasts on
comparison with sample cultured in normal conditions. There was a non-significant difference in VEGF level in hypoxic controls compared to
hypoxic patient fibroblasts (FC = 1.3, P = 0.2). Error bards indicate mean ± SEM *P < 0.05, **P < 0.01.
216 R. Raman et al.
NAN 2015; 41: 201–226© 2014 The Authors. Neuropathology and Applied Neurobiology published by John Wiley & Sons Ltd
on behalf of British Neuropathological Society
genetic background of disease is unknown. Having estab-
lished that the differentially expressed genes in the fibro-
blasts belong to biological processes previously implicated
in disease pathogenesis within the CNS, comparative data
analysis allowed the identification of transcripts in multi-
ple biological pathways which are in common or specifi-
cally differentially expressed in SALS compared to PLS.
The microarray results show that there is a similar per-
centage of genes expressed in SALS, PLS and control fibro-
blasts; however, there are almost twice as many genes
differentially expressed in ALS fibroblasts compared to
controls, than PLS fibroblasts compared to controls (SALS
=416 vs. PLS = 209), and of those altered in PLS, 56% are
also altered in ALS. This result emphasizes that whilst the
two diseases are differentiated clinically by the involve-
ment of the LMN (ALS) or not (PLS), there is considerable
overlap in the pathophysiological mechanisms of disease.
In addition, SALS fibroblasts demonstrate a more severe
phenotype than the PLS fibroblasts, in terms of gene
expression, mirroring the clinical phenotype. Categoriza-
tion of the differentially expressed transcripts demon-
strated that they represented genes in a wide variety of
biological processes, of which the top 3 categories with the
greatest number of gene expression changes, in both
SALS and PLS, were transcription, signalling and metabo-
lism. In contrast, the number of genes involved in RNA
processing and the response to stress was significantly
increased in SALS fibroblasts; these two biological pro-
cesses have been implicated in ALS pathogenesis previ-
ously, further demonstrating the ability of peripheral
tissues to recapitulate characteristics of the CNS in the
ALS disease state.
Metabolic dysfunction
Analysis of the differentially expressed metabolic genes in
SALS fibroblasts suggested that there was a decrease in the
availability of glucose to the cells, as suggested by the
reduced expression of the insulin signalling receptors IR
and IGFR1, both of which activate the glucose uptake
pathway, and decreased expression of the glucose trans-
porter SLC2A3/GLUT3. This is predicted to cause
dysregulation of glycolysis, which would lead to a reduc-
tion in pyruvate entering the mitochondria. With the
associated decreased expression in the key TCA cycle
enzyme DLST, this would lead to diminished aerobic oxi-
dation of energy substrates such as glucose, resulting in
reduced mitochondrial oxygen consumption in SALS
fibroblasts. Indeed, the consequences of the gene expres-
sion changes were supported by the functional data which
showed that SALS patients had significantly reduced
mitochondrial respiration compared to controls, sugges-
tive of a reduction in oxidative phosphorylation. The SALS
cases also showed reduced glycolytic capacity compared to
controls, indicating that SALS fibroblasts have a reduced
ability to up-regulate glycolysis in the presence of the
energy deficit produced by ATP synthase inhibition, due to
decreased expression of key glycolytic enzymes. An
increased AMP : ATP ratio produced by the reduction in
mitochondrial respiration observed in the SALS fibroblasts
could not be regulated to the same degree as in control
patients, due to the down-regulation in SALS fibroblasts of
the PRKAA2 subunit of AMPK, a key metabolic check-
point regulator. Under normal circumstances, AMPK
would counteract the increase in AMP : ATP ratio by
increasing energy substrate catabolism. However the
down-regulation of this gene in SALS patients indicates
that metabolic regulation is defective in these patients,
which is confirmed by the bioenergetic mitochondrial
assays. Therefore, a defective glucose oxidation pathway
leading to mitochondrial defects may be overcome by
switching substrate energy metabolism to fatty acid oxi-
dation. The microarray data suggest that this is indeed the
case, with expression of genes controlling fatty acid syn-
thesis being down-regulated and up-regulation of genes
involved in fatty acid transport and oxidation up-regulated
in the SALS patients.
Alterations in fatty acid oxidation have been observed in
both animal models and ALS patients. Recent work focus-
sing on delta-9 desaturase (SCD1), the rate-limiting
enzyme in monounsaturated fatty acids synthesis has
shown that SCD1 gene expression levels are reduced in
SOD1 G86R mice muscle, ALS patients and by sciatic
nerve crush in mice [39,40]. Knockout SCD1 mice show
an increase in the gene levels of PGC1-a, PPARa and
PDK4, indicating an increase in mitochondrial biogenesis
and a switch from glucose to fatty acids as an energy
source in the muscle [41].
It is difficult at this stage to determine what is cause and
what is effect in terms of ALS metabolic dysfunction. In
normal tissues the glucose-fatty acid cycle is a complex
biochemical mechanism that controls fuel selection and
can dynamically adapt depending on the substrate supply.
Both pathways can inhibit each other, with the possibility
that up-regulation of fatty acid oxidation would lead to
inhibition of glucose oxidation and could potentially lead
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to glucose intolerance and therefore insulin resistance,
which has been observed in ALS cases [42–44]. However,
the metabolic switching at a gene level observed in the
patient fibroblasts away from aerobic glucose oxidation to
fatty acid oxidation in this study may represent an inher-
ent ‘metabolic flexibility’ to try to adapt to and compensate
for the disease state, which may not be present in the CNS
of ALS patients to the same extent. Increased fatty acid
oxidation, either as a direct cause of the disease or a con-
sequence of down-regulation of GLUT3 or glucose intol-
erance in ALS patients [43], may lead to reduced fat
storage which is observed in ALS patients as disease pro-
gresses [45,46] and could lead to dyslipidemia which is a
prognostic factor in the disease [47].
However, there are a number of conflicting reports sur-
rounding dyslipidemia and its role in ALS disease progres-
sion, which may be due to differing populations, sex,
inclusion criteria, study design and the heterogeneity of
the disease [47–50]. If SALS patients try to rely more on
fatty acid oxidation to meet their energy needs, then, as
observed in the G93A mouse model [51], a high fat diet
may prove beneficial. Interestingly, a recent study by Dorst
and colleagues showed that a high calorie dietary supple-
mentation regime stabilizes body weight in ALS patients.
However, a high carbohydrate diet produced similar
results to a high fat diet [52]. Healthy adults tend to have
balanced energy intake and expenditure leading to a
stable body mass index (BMI) and stable energy stores
[44]. This is not the case in ALS patients, where dysphagia
can lead to reduced food intake and hypermetabolism of
patients is often but not always observed [44,53]. This
imbalance would drastically reduce fat stores, especially if
cells are relying on fatty acid oxidation to meet their
energy needs as suggested by our microarray data. This
would lead to loss of body weight and a lower BMI, which
has been observed in ALS patients, with lower BMI being
associated with faster disease progression [54]. Therefore,
a high calorie diet, whether carbohydrate or fat based, is
suggested to be beneficial at a metabolic cellular level pro-
viding increased fuel to help patients maintain their body
weight for longer.
Whilst switching to a high fat diet has been shown to be
beneficial in mutant SOD1 mice by increasing survival
times and hydroxybutyrate treatment in the SOD1 mice
increased body weight, motor neurone counts and
increased ATP synthesis in purified mitochondria [51,55].
Recent studies however have shown that pre-symptoma-
tic mice fed the omega-3-polyunsaturated fatty acid
eicosapentaenoic acid (EPA), which had previously been
shown to have neuroprotective potential in rats [56,57],
led to a decreased life span in G93A SOD1 mice. EPA
increased 4-hydroxy-nonenal (HNE) levels in microglia
and led to increased vacuolization in the dorsal and ventral
horn but no loss of motor neurones [58]. Interestingly
when fed at symptom onset, EPA had no significant effect
on G93A SOD1 mice in terms of disease onset or survival.
These data indicate the complex nature of cellular
energy metabolism, which is constantly in flux. It is still
unclear how ALS affects the interplay between these path-
ways at a molecular level, especially in the neurone as the
disease progresses, and how the disease affects the meta-
bolic response to energy supplementation. Our work using
both SOD1 [59] and SALS fibroblasts as models for ALS
provide insight into how the disease affects the metabo-
lism of peripheral tissues which share the same genetic
background, show disease specific metabolic phenotypes
but not the toxicity observed in the cells in the CNS. This
knowledge may allow us to manipulate the energy gener-
ating pathways in the neurone and ameliorate the
observed metabolic dysfunction.
RNA processing and miRNA dysregulation
Altered RNA processing emerged as a key pathogenic
mechanism in ALS, with the identification of the genes
encoding the RNA binding proteins TDP-43 and FUS as
causes of familial ALS and TDP-43 as a major component
of the ubiquitinated protein inclusions. More recently,
mutations in hnRNPA1 have been reported in ALS [60], as
well as in the RNA binding proteins TATA box binding
protein associated factor 15 (TAF15) [61] and Ewing
sarcoma breakpoint region 1 (EWSR1) [62], both of which
belong to the same protein family as FUS. In addition, the
expanded G4C2 repeat in C9ORF72 may cause pathogenic-
ity through an RNA toxicity mechanism, sequestering
RNA binding proteins from the cytoplasm [63]. Thus,
following on from the earlier literature identifying
angiogenin (ANG) [64] and senataxin (SETX) [65] as RNA-
related proteins which are mutated in ALS, there is now
substantial evidence of dysregulated RNA processing con-
tributing to the pathogenesis of both genetic and sporadic
ALS [66,67]. Of the 28 differentially expressed genes
which encode proteins related to RNA processing, all
except 4 were decreased in SALS fibroblasts. Multiple RNA
binding proteins, including FUS and several hnRNPs
(though not hnRNPA1) were decreased, thereby providing
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evidence of dysregulated RNA processing occurring not
only in the CNS but also in peripheral tissues of SALS
patients. A potential effect of the reduction in expression of
these RNA processing genes is a reduction in transcription,
and of the 416 significant differentially expressed genes
identified, the majority, 354 genes (85%) are decreased.
Transcriptional repression has been described previously
in ALS, both in a SOD1-related cell model [68] and mouse
model [69]. The data presented here suggest that this is a
phenomenon which can extend to sporadic disease.
Multiple components of the miRNA processing
pathway were also found to be specifically differentially
expressed in the SALS fibroblasts. Whilst the fold changes
in gene expression were not large (range −1.52 to −2.22),
they produced a significant effect on the level of multiple
miRNA transcripts, with all 19 of the differentially
expressed miRNAs in ALS fibroblasts showing reduced
expression. Interestingly, 5 of these miRNAs, for which
functions have been described, are involved in hypoxia and
either regulate HIF1A or HIF1B expression or are regu-
lated themselves by HIF1A, further supporting a
dysregulation in ALS of the hypoxia response (see below).
miRNAs are stable non-protein coding RNA molecules
known to post-transcriptionally regulate several target
mRNA transcripts, usually by binding to the 3′UTR
sequence to inhibit translation. The RNA binding proteins
TDP-43 and FUS have both been shown to bind to the
microprocessor complex subunit DROSHA, DICER and
pri-miRNA sequences, thereby implicating miRNA in the
pathophysiology of ALS [35,70,71]. miRNAs have also
been shown to be an essential component of post-mitotic
neurones, as DICER knockout in Purkinje cells led to pro-
gressive neurodegeneration [72], whilst DICER knockout
specifically in post-mitotic postnatal motor neurones was
associated with muscular atrophy due to loss of lumbar
motor neurones, increased astrogliosis and progressive
neurodegeneration.
miRNAs have been shown to be both protective and
deleterious in ALS. miR-206 expression in the skeletal
muscle of SOD1G93A ALS mouse model was found to be
increased during disease progression but knockdown
exacerbated the disease, as miR-206 is thought to be
involved in muscle re-innervation [73]. In contrast, a sig-
nificant increase in miR-155 was seen in rat and mouse
SOD1G93A models as well as human ALS spinal cord. Use of
anti-miR-155, however, extended survival and disease
duration, though the mechanism by which this occurs has
yet to be established. In contrast to the increased levels
observed in the spinal cord, the SALS fibroblasts showed a
decrease in miR-155 expression, reflecting perhaps a cell
type specific response in the fibroblasts, as spleen from
SOD1G93A ALS mouse as well as monocytes from ALS
patients, also show increases in miR-155 [37].
Interestingly, however, 13 of the miRNAs differentially
expressed in SALS fibroblasts were also shown to be
decreased in spinal cord of SALS cases. As with the fibro-
blast miRNA profiling, there was a significant reduction in
the expression of miRNAs in the SALS spinal cord, with
239/245 significantly differentially expressed miRNAs
decreased in expression, whilst only 6, (but not miRNA-
155) were increased [35]. In addition, 10 of the miRNAs
that were differentially expressed in the SALS fibroblasts
were also decreased in a neuroblastoma knockdown
model of FUS [37]; FUS expression has also been shown to
be decreased in these fibroblasts. Dysregulation of
miRNAs which specifically bind to TDP-43 have also been
shown to be dysregulated in the cerebrospinal fluid and
serum of SALS cases, as well as in immortalized
lymphoblastoid cell lines from patients with mutations in
TARDBP, FUS, SOD1 and C9ORF72 [74]. Thus, there is
mounting evidence of dysregulation in miRNA expression
in sporadic and genetic subtypes of ALS, as well as in other
neurodegenerative disorders [75].
Hypoxia and the response to stress
Evidence of hypoxia playing a role in the pathogenesis of
ALS has been mounting following the serendipitous
finding that deletion of the HIF-1 binding site in the pro-
moter of VEGF of the mouse resulted in a progressive
neurodegenerative phenotype reminiscent of ALS [76].
VEGF has been shown to have a neuroprotective effect
on motor neurones [77], not only through the formation
of micro-vessels increasing the blood supply to motor
neurones, but also through a direct interaction with
neuropilin-1 [76]. Subsequently, it has been shown that
VEGF levels in the CSF of hypoxaemic ALS patients are
decreased compared to controls [78], whilst levels of both
HIF1A mRNA and protein fail to increase following
hypoxia in monocytes from SALS patients [79]. The SALS
fibroblasts, similar to the monocytes, also fail to exhibit
increased HIF1A protein expression following hypoxia, as
well as an increase in VEGF protein. Thus, there is a sig-
nificant failure by ALS tissues to respond to hypoxia, but
where along the hypoxia response pathway this failure lies
is currently unclear.
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Within the spinal cord of the SOD1G93A ALS mouse
model, HIF1A levels have actually been shown to increase,
but most significantly in the glial cells surrounding the
anterior horn motor neurones [80]. However, whilst these
changes were detected at the early symptomatic stage, the
subsequent hypoxia response, as measured by VEGF
expression was only evident at the end stage of disease and
only within the glial cells. Thus, motor neurones (in addi-
tion to fibroblasts) appear to lack the neuroprotective
response to hypoxia. The lack of this response, even when
the hypoxia is chronic, has been shown to have significant
effects in the SOD1G93A ALS mouse model. Mutant SOD1
mice which experienced chronic intermittent hypoxia
showed reduced performance on the rotarod, reduced
ability in the wire hanging test, poorer spatial memory as
assessed by the Y-maze, and a greater loss of motor neu-
rones, compared to the SOD1G93A mice under normoxia
conditions [81]. This correlates with data recorded from
ALS patients, which compared nocturnal hypoxia with
cognitive dysfunction [82]. The results demonstrated that
patients who experience nocturnal hypoxia (as defined as
the average O2 saturation being <95% for more than 10%
of the sleep time) showed a significant decrease in their
memory retention and retrieval efficiency abilities. Inter-
estingly, the use of non-invasive ventilation has been
reported to improve cognitive function of patients [83] as
well as survival [84]. Therefore, it is suggested that this
improved survival may be in part be due to the reduction
of the patient being exposed to hypoxia, to which they are
unable to mount an optimal response.
The use of fibroblasts as a cell model
The aims of this investigation included determining
whether the dysregulated biological pathways in fibro-
blasts were consistent with the diseased tissue in the CNS,
and therefore to establish whether fibroblasts could act as
a cellular model for subtypes of ALS where genetic mod-
elling of the disease is not possible. The microarray data
presented clearly shows that, particularly in SALS fibro-
blasts, the differentially expressed genes do correlate with
biological pathways known to be dysregulated in
the motor neurones and spinal cord of ALS cases. The
microarray data in this report, in combination with the
functional data, clearly show dysregulation of miRNA
processing and the response to hypoxia as severely dis-
rupted specifically in SALS fibroblasts, and this recapitu-
lates pathways which have been reported as being
dysregulated in the CNS of ALS cases [35,79]. Therefore,
fibroblasts can provide a valuable cellular model of SALS
or in instances where generation of a standard over-
expression cellular model, such as the large expansions of
the GGGGCC repeat in C9ORF72 or over-expression of
wild type and mutant TARDBP, have proven challenging.
Fibroblasts have become a commonly used cell from
which to derive induced pluripotent stem cells (iPSCs)
with subsequent generation of neurones and glia.
Neuronal cells have been differentiated from SOD1, VAPB,
TARDBP and C9ORF72-related ALS patients [85–88],
and astrocytes have been differentiated from SOD1 and
TARDBP neuronal progenitor cells [89,90]. Whilst this
strategy offers a cellular model with the genetic back-
ground of a patient within a neuronal (or glial) cell type,
there are still some difficulties regarding the variability
between different clones generated from the same indi-
vidual, which are currently limiting their use as a robust
and reliable model for gene expression analysis or high
throughput drug screening. This is illustrated in a recent
report where the expression levels of TARDBP were shown
to be variable in each of 3 clones from 3 different TDP-43
mutation biosamples [91]. In contrast, fibroblasts have
been used to screen a library of 2000 compounds for a
compound able to rescue the mitochondrial dysfunction
seen in Parkinson’s disease [92]. Using parkin-mutant
fibroblasts for the initial drug screening strategy,
ursocholanic acid was shown to rescue the mitochondrial
dysfunction and actually increase the activity of com-
plexes I-IV in these fibroblasts. Further work also showed
the mitochondrial respiratory chain was rescued in
LRRK2-mutant fibroblasts, thereby widening the poten-
tial of this small molecule compound to provide some level
of compensation for the mitochondrial dysfunction seen
in multiple subtypes of Parkinson’s disease.
In conclusion, we have established that fibroblasts can
be used as a cellular model for ALS and PLS as they reca-
pitulate previously determined dysregulated biological
pathways in the CNS, and through using gene expression
profiling in this study, we have provided a more detailed
understanding (at the gene level) of the basis of these
changes. We have demonstrated that whilst there are
transcriptional changes common to both SALS and PLS in
metabolic genes, there is marked transcriptional repres-
sion in the SALS fibroblasts, which is associated with an
enrichment of differentially expressed genes which are
involved in RNA processing and the response to stress.
Therefore, we propose that fibroblasts can act as a disease
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model, particularly where genetic modelling is not possi-
ble or challenging, (so long as the relevant gene is
expressed in this cell type), to study pathophysiological
mechanisms, to identify targets amenable to therapeutic
intervention and to screen for disease modifying drugs.
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